Stabilization of protein-protein interactions by small molecules

Drug Discovery Today

Volumn 19, Issue 11, 2014, Pages 1812-1821

  Giordanetto, Fabrizio ^a   Schäfer, Anja ^b   Ottmann, Christian ^b  

^a Medicinal Chemistry Taros Chemicals   (Germany)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1EBIO; BREFELDIN; COTYLENIN A; CYCLOSPORIN A; DEXTRO MYO INOSITOL (1,4,5,6) TETRAKISPHOSPHATE; FORSKOLIN; FUSICOCCIN; FUSICOCCIN A; INOSITOL TETRAKISPHOSPHATE; NATURAL PRODUCT; O METHOXY NUCLEOZIN; PHENOTHIAZINE DERIVATIVE; RAPAMYCIN; RAZOXANE; RO 2443; TACROLIMUS; TAFAMIDIS; UNCLASSIFIED DRUG; DRUG; PROTEIN;

ANTIVIRAL ACTIVITY; CRYSTAL STRUCTURE; DRUG ACTIVITY; ENZYME ACTIVITY; GENOME; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; PROTEIN STABILITY;

DRUG DISCOVERY; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEIN STABILITY; PROTEINS;

EID: 84910596652     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.08.005     Document Type: Review

References (102)

1. V. Azzarito Inhibition of α-helix-mediated protein-protein interactions using designed molecules Nat. Chem. 5 2013 161 173
2. A.A. Ivanov Targeting protein-protein interactions as an anticancer strategy Trends Pharmacol. Sci. 34 2013 393 400
3. J.A. Wells, and C.L. McClendon Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 450 2007 1001 1009
4. P. Secchiero Recent advances in the therapeutic perspectives of nutlin-3 Curr. Pharm. Des. 17 2011 569 577
5. L.T. Vassilev In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848
6. T. Oltersdorf An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 435 2005 677 681
7. C.M. Rudin Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 18 2012 3163 3169
8. C. Tse ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res. 68 2008 3421 3428
9. F. Christ Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication Nat. Chem. Biol. 6 2010 442 448
10. G. Zimmermann Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling Nature 497 2013 638 642
11. M.M. He Small-molecule inhibition of TNF-α Science 310 2005 1022 1025
12. P. Filippakopoulos Selective inhibition of BET bromodomains Nature 468 2010 1067 1073
13. L. Von Kleist Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition Cell 146 2011 471 484
14. P. Thiel Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery? Angew. Chem. Int. Ed. 51 2012 2012 2018
15. J.F. Borel Biological effects of cyclosporin A: a new antilymphocytic agent Agents Actions 6 1976 468 475
16. R. Zocher Biosynthesis of cyclosporin A: partial purification and properties of a multifunctional enzyme from Tolypocladium inflatum Biochemistry 25 1986 550 553
17. G. Fricker Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation Br. J. Pharmacol. 118 1996 1841 1847
18. R.M. Wenger Cyclosporine: chemistry, structure-activity relationships and mode of action Metabolic Control in Diabetes Mellitus Beta Adrenoceptor Blocking Drugs NMR Analysis of Cancer Cells Immunoassay in the Clinical Laboratory Cyclosporine 1986 Springer Berlin/Heidelberg 157 191
19. J.R. Jeffery Cyclosporine analogues Clin. Biochem. 24 1991 15 21
20. T. Lazarova, and Z. Weng Cyclosporin A analogues: recent advances Expert Opin. Ther. Pat. 13 2003 1327 1332
21. H.F. Stähelin The history of cyclosporin A (Sandimmune) revisited: another point of view Experientia 52 1996 5 13
22. R.E. Handschumacher Cyclophilin: a specific cytosolic binding protein for cyclosporin A Science 226 1984 544 547
23. P.A. Gallay, and K. Lin Profile of alisporivir and its potential in the treatment of hepatitis C Drug Des. Dev. Ther. 7 2013 105 115
24. J. Liu Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes Cell 66 1991 807 815
25. Q. Huai Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes Proc. Natl. Acad. Sci. U. S. A. 99 2002 12037 12042
26. T. Kino FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics J. Antibiot. 40 1987 1249 1255
27. M.T. Goulet The medicinal chemistry of FK-506 Perspect. Drug Discov. Des. 2 1994 145 162
28. J.J. Siekierka A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin Nature 341 1989 755 757
29. J.P. Griffith X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex Cell 82 1995 507 522
30. S.N. Sehgal Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization J. Antibiot. 28 1975 727 732
31. R.R. Martel Inhibition of the immune response by rapamycin, a new antifungal antibiotic Can. J. Physiol. Pharmacol. 55 1977 48 51
32. E.J. Brown A mammalian protein targeted by G1-arresting rapamycin-receptor complex Nature 369 1994 756 758
33. J. Choi Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP Science 273 1996 239 242
34. J.I. Luengo Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interface Chem. Biol. 2 1995 471 481
35. J.H. Bayle Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity Chem. Biol. 13 2006 99 107
36. D. Benjamin Rapamycin passes the torch: a new generation of mTOR inhibitors Nat. Rev. Drug Discov. 10 2011 868 880
37. F. Giordanetto, and J. Kihlberg Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? J. Med. Chem. 57 2014 278 295
38. S.V. Bhat Structures and stereochemistry of new labdane diterpiniods from coleus forskohlii briq Tetrahedron Lett. 18 1977 1669 1672
39. K.B. Seamon Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells Proc. Natl. Acad. Sci. U. S. A. 78 1981 3363 3367
40. R.K. Sunahara Interaction of Gsalpha with the cytosolic domains of mammalian adenylyl cyclase J. Biol. Chem. 272 1997 22265 22271
41. G. Zhang Structure of the adenylyl cyclase catalytic core Nature 386 1997 247 253
42. J.J. Tesmer Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS Science 278 1997 1907 1916
43. A. Laurenza Stimulation of adenylate cyclase by water-soluble analogues of forskolin Mol. Pharmacol. 32 1987 133 139
44. T. Tatee Forskolin derivatives. I. Synthesis, and cardiovascular and adenylate cyclase-stimulating activities of water-soluble forskolins Chem. Pharm. Bull. 44 1996 2274 2279
45. Y. Toya Forskolin derivatives with increased selectivity for cardiac adenylyl cyclase J. Mol. Cell. Cardiol. 30 1998 97 108
46. C. Pinto Activation and inhibition of adenylyl cyclase isoforms by forskolin analogs J. Pharmacol. Exp. Ther. 325 2008 27 36
47. A. Ballio Fusicoccin: a new wilting toxin produced by Fusicoccum amygdali Del Nature 203 1964 297
48. T. Sassa Isolation of a new plant growth substance with cytokinin-like activity Nature 227 1970 379
49. L. Camoni The phytotoxin fusicoccin, a selective stabilizer of 14-3-3 interactions? IUBMB Life 65 2013 513 517
50. A.H. De Boer, and I.J. de Vries-van Leeuwen Fusicoccanes: diterpenes with surprising biological functions Trends Plant Sci. 17 2012 360 368
51. L-G. Milroy Stabilization and inhibition of protein-protein interactions: the 14-3-3 case study ACS Chem. Biol. 8 2013 27 35
52. I.J. De Vries-van Leeuwen Fusicoccin-A selectively induces apoptosis in tumor cells after interferon-alpha priming Cancer Lett. 293 2010 198 206
53. L. Camoni The phytotoxin fusicoccin promotes platelet aggregation via 14-3-3-glycoprotein Ib-IX-V interaction Biochem. J. 436 2011 429 436
54. I.J. De Vries-van Leeuwen Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface Proc. Natl. Acad. Sci. U. S. A. 110 2013 8894 8899
55. Y. Honma Cotylenin A - a plant growth regulator as a differentiation-inducing agent against myeloid leukemia Leuk. Lymphoma 43 2002 1169 1178
56. T. Kasukabe Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts Breast Cancer Res. 7 2005 R1097 R1110
57. C. Ottmann A structural rationale for selective stabilization of anti-tumor interactions of 14-3-3 proteins by cotylenin A J. Mol. Biol. 386 2009 913 919
58. M. Molzan Stabilization of physical RAF/14-3-3 interaction by cotylenin A as treatment strategy for RAS mutant cancers ACS Chem. Biol. 8 2013 1869 1875
59. C. Anders A semisynthetic fusicoccane stabilizes a protein-protein interaction and enhances the expression of K+ channels at the cell surface Chem. Biol. 20 2013 583 593
60. K. Kawakami A novel fusicoccin derivative preferentially targets hypoxic tumor cells and inhibits tumor growth in xenografts Anticancer Agents Med. Chem. 12 2012 791 800
61. T. Toyomasu Fusicoccins are biosynthesized by an unusual chimera diterpene synthase in fungi Proc. Natl. Acad. Sci. U. S. A. 104 2007 3084 3088
62. J. Arens Exploration of biosynthetic access to the shared precursor of the fusicoccane diterpenoid family Chem. Commun. 49 2013 4337 4339
63. C. Johnson Visualization and biochemical analyses of the emerging mammalian 14-3-3-phosphoproteome Mol. Cell. Proteomics MCP 10 2011 M110.005751
64. M.M. Nalaskowski The human homologue of yeast ArgRIII protein is an inositol phosphate multikinase with predominantly nuclear localization Biochem. J. 366 2002 549 556
65. L. Eckmann d-Myo-inositol 1,4,5,6-tetrakisphosphate produced in human intestinal epithelial cells in response to Salmonella invasion inhibits phosphoinositide 3-kinase signaling pathways Proc. Natl. Acad. Sci. U. S. A. 94 1997 14456 14460
66. P.J. Watson Structure of HDAC3 bound to co-repressor and inositol tetraphosphate Nature 481 2012 335 340
67. R. Ishida DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae Cancer Res. 55 1995 2299 2303
68. G. Weiss Dexrazoxane (ICRF-187) Gen. Pharmacol. Vasc. Syst. 32 1999 155 158
69. J. Roca Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp Proc. Natl. Acad. Sci. U. S. A. 91 1994 1781 1785
70. S. Classen Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 Proc. Natl. Acad. Sci. U. S. A. 100 2003 10629 10634
71. S.M. Johnson Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses Acc. Chem. Res. 38 2005 911 921
72. S. Connelly Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses Curr. Opin. Struct. Biol. 20 2010 54 62
73. H. Razavi Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action Angew. Chem. Int. Ed. Engl. 42 2003 2758 2761
74. C.E. Bulawa Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade Proc. Natl. Acad. Sci. U. S. A. 109 2012 9629 9634
75. S.C. Garrett A biosensor of S100A4 metastasis factor activation: inhibitor screening and cellular activation dynamics Biochemistry 47 2008 986 996
76. S.P. Massie The chemistry of phenothiazine Chem. Rev. 54 1954 797 833
77. A. Jaszczyszyn Chemical structure of phenothiazines and their biological activity Pharmacol. Rep. 64 2012 16 23
78. F. López-Muñoz History of the discovery and clinical introduction of chlorpromazine Ann. Clin. Psychiatry 17 2005 113 135
79. V.N. Malashkevich Phenothiazines inhibit S100A4 function by inducing protein oligomerization Proc. Natl. Acad. Sci. U. S. A. 107 2010 8605 8610
80. T. Noda Architecture of ribonucleoprotein complexes in influenza A virus particles Nature 439 2006 490 492
81. R.Y. Kao Identification of influenza A nucleoprotein as an antiviral target Nat. Biotechnol. 28 2010 600 605
82. C.-Y. Su High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity Proc. Natl. Acad. Sci. U. S. A. 107 2010 19151 19156
83. S.W. Gerritz Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers Proc. Natl. Acad. Sci. U. S. A. 108 2011 15366 15371
84. M. Wade The p53 orchestra: Mdm2 and Mdmx set the tone Trends Cell Biol. 20 2010 299 309
85. C.J. Brown Awakening guardian angels: drugging the p53 pathway Nat. Rev. Cancer 9 2009 862 873
86. M. Wade, and G.M. Wahl Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol. Cancer Res. 7 2009 1 11
87. B. Graves Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization Proc. Natl. Acad. Sci. U. S. A. 109 2012 11788 11793
88. X.M. Xia Mechanism of calcium gating in small-conductance calcium-activated potassium channels Nature 395 1998 503 507
89. A.H. Weston Impairment of endothelial SK(Ca) channels and of downstream hyperpolarizing pathways in mesenteric arteries from spontaneously hypertensive rats Br. J. Pharmacol. 160 2010 836 843
90. K.G. Chandy Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate for schizophrenia and bipolar disorder? Mol. Psychiatry 3 1998 32 37
91. M. Zhang Identification of the functional binding pocket for compounds targeting small-conductance Ca2+-activated potassium channels Nat. Commun. 3 2012 1021
92. P. Pedarzani, and M. Stocker Molecular and cellular basis of small - and intermediate - conductance, calcium-activated potassium channel function in the brain Cell. Mol. Life Sci. 65 2008 3196 3217
93. D. Strøbæk Activation of human IK and SK Ca2+-activated K+ channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime) Biochim. Biophys. Acta - Biomembr. 1665 2004 1 5
94. H. Gronemeyer Principles for modulation of the nuclear receptor superfamily Nat. Rev. Drug Discov. 3 2004 950 964
95. D. DeManno Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy Steroids 68 2003 1019 1032
96. K.P. Madauss A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator Mol. Endocrinol. 21 2007 1066 1081
97. P. Germain Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists Chem. Biol. 16 2009 479 489
98. A. Le Maire A unique secondary-structure switch controls constitutive gene repression by retinoic acid receptor Nat. Struct. Mol. Biol. 17 2010 801 807
99. R. Rose Identification and structure of small-molecule stabilizers of 14-3-3 protein-protein interactions Angew. Chem. Int. Ed. Engl. 49 2010 4129 4132
100. G. Zinzalla, and D.E. Thurston Targeting protein-protein interactions for therapeutic intervention: a challenge for the future Future Med. Chem. 1 2009 65 93
101. U. Stelzl A human protein-protein interaction network: a resource for annotating the proteome Cell 122 2005 957 968
102. A. Patil Hub promiscuity in protein-protein interaction networks Int. J. Mol. Sci. 11 2010 1930 1943